DG70

DG70 (GSK1733953A), a biphenyl amide, is a respiration inhibitor in Mycobacterium tuberculosis, inhibits MenG activity with an IC50 value of 2.6 ± 0.6 μM. DG70 inhibits the catalytic methylation of Mycobacterium tuberculosis demethylmenaquinone methyltransferase enzymes. DG70 can be used for Tuberculosis (TB) research[1][2][3].

Product Specifications

CAS Number

[930470-97-6]

Product Name Alternative

GSK1733953A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/dg70.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(C2=CC=C(OC)C=C2)=C(OC)C=C1)C3=CC=C(F)C=C3Cl

Molecular Formula

C21H17ClFNO3

Molecular Weight

385.82

Precautions

H302, H315, H319, H335

References & Citations

[1]Pujari V, et al. Mycobacterial MenG: Partial Purification, Characterization, and Inhibition. ACS Infect Dis. 2022 Dec 9;8 (12) :2430-2440. |[2]Adewumi AT, et al. Thompson loop: opportunities for antitubercular drug design by targeting the weak spot in demethylmenaquinone methyltransferase protein. RSC Adv. 2020 Jun 19;10 (39) :23466-23483. |[3]Sukheja P, et al. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells. mBio. 2017 Feb 14;8 (1) :e02022-16.